Vanda Pharmaceuticals is in a legal battle with the FDA over the approval of generic versions of its sleep disorder drug, Hetlioz. Vanda claims that the generics were approved without sufficient evidence and is now urging FDA Commissioner Marty Makary to review the decision personally.
Hetlioz, containing the active ingredient tasimelteon, was initially approved in 2014 for sleep-wake disorder. Vanda sought to expand its label to include jet lag disorder in 2018, but the FDA rejected the application in 2019. Following an appeal and subsequent legal action, a federal court ruled in Vanda’s favor in 2022, stating that the drug showed efficacy in improving sleep disturbance.
Despite this legal victory, Vanda is now challenging the FDA’s approval of generic versions of Hetlioz. The company alleges that the approvals were granted based on flawed studies and data. Both MSN Pharmaceuticals and Teva Pharmaceuticals have received FDA approval for generics containing tasimelteon, leading Vanda to file a citizen petition requesting the revocation of these decisions.
Vanda’s petition highlighted concerns such as limited testing in specific populations and failure to meet bioequivalence requirements. The FDA denied the petition in June, upholding its decision to approve the generics. Vanda criticized the FDA’s stance, claiming that the agency’s approval process for generics lacked proper scrutiny and adherence to legal standards.
In light of these developments, Vanda is calling on FDA Commissioner Makary to reassess the approval of the generic versions of Hetlioz. The company is seeking a fair and thorough review of the approval process, emphasizing the importance of upholding legal standards and ensuring that generic drugs meet the necessary requirements for safety and efficacy.
Vanda’s legal battle with the FDA underscores the complexities and challenges in the pharmaceutical regulatory landscape. The case highlights the importance of robust evidence and adherence to regulatory standards in drug approval processes. As the biotech industry continues to evolve, ensuring the integrity of the drug approval process is crucial for maintaining public trust and safeguarding patient health.
- Vanda Pharmaceuticals challenges FDA’s approval of generics for Hetlioz after legal victory
- Allegations of flawed studies and data in generic approvals raise concerns about regulatory standards
- Call for FDA Commissioner Makary to review and uphold legal standards in drug approval processes
- Importance of maintaining integrity and transparency in pharmaceutical regulatory practices
Tags: biotech
Read more on biospace.com